GlobalData on MSN3d
FDA grants accelerated approval to Novartis’ Vanrafia for IgAN
The approval is supported by a prespecified interim analysis from the ongoing, randomised Phase III ALIGN trial.
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.
Novartis gets FDA accelerated approval for kidney disease treatment
Novartis ( NYSE: NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...
The Pharma Letter3d
FDA accelerated approval for Novartis’ Vanrafia
Swiss pharma giant Novartis (NOVN: VX) today announced the US Food and Drug Administration (FDA) has granted accelerated ...
Novartis gets FDA accelerated approval for Vanrafia
Novartis (NVS) “announced the FDA has granted accelerated approval for Vanrafia, or atrasentan, a potent and selective endothelin A receptor ...
Medical Dialogues3d
Novartis receives USFDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy
Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent ...
Seeking Alpha3d
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA ...
Novartis is uniquely positioned to lead a transformation in kidney care Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase III ALIGN study measuring ...
Managed Healthcare Executive3d
FDA Grants Accelerated Approval to Vanrafia for IgAN, a Rare Kidney Disease
Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...
pharmaphorum3d
Novartis gets FDA nod for second of three IgAN drugs
Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...
Medical Dialogues1d
FDA Grants Accelerated Approval to Atrasentan for IgA Nephropathy
The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...
KXAN3d
Novartis receives FDA accelerated approval for Vanrafia®
Novartis is uniquely positioned to lead a transformation in kidney care Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase III ALIGN study measuring ...